Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Verstovsek on the Benefit of JAK Inhibitor Combos in Myelofibrosis

October 13th 2021

Srdan Verstovsek, MD, PhD, discusses the benefit of drug combinations to improve anemia in patients with myelofibrosis.

Dr. Rampal on the Importance of Risk Stratification in Myelofibrosis

October 12th 2021

Raajit K. Rampal, MD, PhD, discusses the importance of risk stratification in myelofibrosis.

FDA Lifts Hold on Rusfertide Clinical Development Program

October 12th 2021

The FDA has removed the full clinical hold that had previously been placed on trials evaluating rusfertide.

Dr. Jamieson on Treatment Considerations in Myelofibrosis

October 7th 2021

Catriona Jamieson, MD, PhD, discusses treatment considerations for patients with myelofibrosis.

Prolonged Overall Survival Observed With Oral Decitabine/Cedazuridine in MDS and CMML

September 24th 2021

Updated data from the phase 3 ASCERTAIN trial demonstrated that the oral, fixed-duration combination of decitabine and cedazuridine induced a median overall survival of 31.7 months in patients with intermediate- and high-risk myelodysplastic syndrome, including chronic myelomonocytic leukemia.

A Changing Tide for Patients With Myelofibrosis

September 14th 2021

The hallmarks of myelofibrosis—including clonal myeloproliferation, bone marrow fibrosis, anemia, splenomegaly, and constitutional symptoms—are associated with risk of morbidity and mortality; however, the recent advent of novel combinations and sequencing strategies have built on the foundation of care established with JAK2 inhibitors.

Transfusion Independence With Momelotinib Could Inform Treatment Decisions in Myelofibrosis

September 14th 2021

The investigational JAK inhibitor momelotinib is effective at treating anemia in patients with myelofibrosis, resulting in improved rates of transfusion independence compared with ruxolitinib.

Future of MPN Research, Treatment Revolves Around Addressing ‘A Main Problem’

September 11th 2021

Although there are several classes of drugs either approved, or in development, for the treatment of myeloproliferative neoplasms, a big question remains.

Dr. Mesa on the Impact of Molecular Biology on Therapeutic Development in Myelofibrosis

September 11th 2021

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

Challenges Remain in Treatment of Accelerated Phase Myeloproliferative Neoplasms

September 10th 2021

Treating patients with accelerated phase myeloproliferative neoplasm is an ongoing therapeutic challenge, due to the lack of standard treatment approaches, according to an expert.

Dr. Verstovsek Discusses Research Efforts in Myelofibrosis-Related Anemia

September 10th 2021

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

MYLOX-1 Trial Opens to Evaluate Novel Anti-Fibrotic Agent GB2064 in Myelofibrosis

September 3rd 2021

The phase 2a MYLOX-1 trial is evaluating GB2064, a novel, oral LOXL2 inhibitor, as a potential anti-fibrotic treatment option for patients with myelofibrosis.

Dr. Rampal on the Importance of Genomic Testing in Myelofibrosis

September 2nd 2021

Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis.

Dr. Mauro on the Risks of Disease Progression in Myelofibrosis

August 31st 2021

Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.

Palbociclib/Ruxolitinib Combo Shows Preclinical Promise in Myelofibrosis

August 19th 2021

Palbociclib plus ruxolitinib led to normalized blood leukocyte counts, reduced splenomegaly, and significantly improved bone marrow fibrosis in JAK2 V617F and MPLW515L mouse models of myelofibrosis, suggesting that the combination could provide therapeutic benefit to patients with the malignancy.

Unmet Needs in Management of Myeloproliferative Neoplasms

August 18th 2021

Pankit Vachhani, MD, reacts to treatment limitations for health care professionals who care for patients with myeloproliferative neoplasms.

Selecting Therapy to Treat Myelofibrosis

August 18th 2021

Patient factors and disease characteristics that impact decisions to treat patients with myelofibrosis with ruxolitinib or fedratinib.

Ruxolitinib for Myelofibrosis: Treatment Considerations

August 18th 2021

Pankit Vachhani, MD, explains how to properly treat myelofibrosis using ruxolitinib based on data provided by key clinical trials like COMFORT-I and COMFORT-II.

Dr. Jamieson on the Importance of Treating at Diagnosis in Myelofibrosis

August 12th 2021

Catriona Jamieson, MD, PhD, discusses the importance of treating patients with myelofibrosis at diagnosis.

Momelotinib Improves Transfusion Independence Rates Vs Ruxolitinib in Anemic, JAK Inhibitor–Naïve Myelofibrosis

August 12th 2021

Jean-Jacques Kiladjian, MD, PhD, discusses the effectiveness of momelotinib compared with ruxolitinib in patients with myelofibrosis who have anemia and are naïve to JAK inhibitors.